China to approve imports of hemophilia treatment

09/20/2007 | China Daily (Beijing)

China plans to approve imports of a Bayer Healthcare recombinant-clotting factor to ease the country's current medication shortage for hemophilia patients. Officials stressed they are not easing an existing ban on imported blood and plasma-derived products because the treatment is not made from human plasma.

View Full Article in:

China Daily (Beijing)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Pompano Beach, FL